Real-Life Dosing of Biologics in Plaque Psoriasis—A German Survey

The study surveyed 100 dermatologists in Germany to evaluate the use and dosing of biologic treatments for plaque psoriasis. Dermatologists treated about 100 psoriasis patients per quarter, with 10% in private practices and 23% in hospitals receiving biologics. The distribution of biologics was etanercept (37%), adalimumab (33%), infliximab (20%), and ustekinumab (10%). About 80% of dosing conformed to product labels, but higher doses were used in 20% of cases due to factors like disease severity, duration, loss of efficacy, overweight, joint involvement, and previous systemic therapies. The study concluded that real-life dosing often deviated from recommended posology, especially for high-need patients.